More News

Jazz Pharmaceuticals to acquire Actio Biosciences and expand rare epilepsy portfolio

Jim Cornall -
Jazz Pharmaceuticals plc and Actio Biosciences, Inc. have entered into a definitive agreement for Jazz to acquire privately-held Actio...

Tagomics introduces cfDNA-based blood test for multi-organ drug safety monitoring

Jim Cornall -
Tagomics Ltd. has launched LiquiPath, a cross-species, multi-organ "liquid pathology" platform, for non-invasive drug safety monitoring. Developed for use across...

Base to Base biotech podcast 71: The IgA/CD89 axis

Jim Cornall -
This week, we have a conversation Paweł Szczepański, CEO of JJP Biologics about specially-built antibodies to tackle autoimmune diseases...

Activating human killer T-cells against cancer

Jim Cornall -
CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that “tricks” the body’s immune system into fighting...

Spinal Muscular Atrophy Awareness Month begins with spotlight on care gaps

Jim Cornall -
As August marks SMA Awareness Month, Cure SMA is drawing attention to its 2025 State of SMA report, an...

University of Aberdeen-led team to trial new drug for heavy menstrual bleeding

Jim Cornall -
Researchers from the Universities of Aberdeen and Edinburgh have been awarded just under £2m to lead a major clinical...

Bristol Myers Squibb announces $2.3bn campus in Texas

Jim Cornall -
Bristol Myers Squibb has announced the selection of Houston, Texas, as the site for a new, multi-modal manufacturing campus,...

Mironid raises $46m to advance clinical development of rare kidney disease treatment

Jim Cornall -
Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease (ADPKD), a...

Foundation for Angelman Syndrome Therapeutics announces agreement with Apertura Gene Therapy for access to blood-brain barrier-crossing capsid

Jim Cornall -
The Foundation for Angelman Syndrome Therapeutics (FAST), a patient advocacy organisation working to support the development of transformative treatment...

3D genome mapping in rare immune cells reveals new Crohn’s genes

Jim Cornall -
A new study co-led by Valeriya Malysheva, group leader at the VIB-UAntwerp Center for Molecular Neurology, has been published...

Cancer cells hijack a fatty acid to escape immune attack in liver metastases

Jim Cornall -
Liver metastases are among the most common and deadly forms of cancer spread. Now, researchers at VIB and KU...

Collaboration aims to develop new class of medicines for in vivo CAR-T

Jim Cornall -
Sail Biomedicines has announced a strategic collaboration with Johnson & Johnson to advance innovative In Vivo Chimeric Antigen Receptor...

Data validates new method for single-cell transcriptomic tumour profiling from clinical pathology samples

Jim Cornall -
One Biosciences has announced data establishing that single-cell RNA expression profiles can be generated from the standard, formalin-fixed paraffin-embedded...

White paper looks at early clinical development of B-cell depletion therapies in autoimmune disease

Jim Cornall -
Novotech, a clinical research organisation (CRO) and scientific advisory company, has released a new white paper, B-Cell Depletion in...

3D genome mapping in rare immune cells reveals new Crohn’s disease genes

Jim Cornall -
A new study co-led by Valeriya Malysheva, group leader at the VIB-UAntwerp Center for Molecular Neurology, has been published...

Elix and University of Vienna agree to use AI to advance drug discovery

Jim Cornall -
Elix, Inc. and the University of Vienna, Austria, have signed a joint research agreement aimed at advancing drug discovery...

KAIST develops way to combat cancer cachexia

Jim Cornall -
A new path has opened toward stopping cancer-associated cachexia, a devastating complication that gradually wastes patients away. A KAIST...

A better way to deliver mitochondria into living cells

Jim Cornall -
Inside almost every cell in our body are tiny structures called organelles that keep us alive and functioning. Among...

Thyora Therapeutics launches to build platform for covalent drug discovery

Jim Cornall -
Thyora Therapeutics has emerged from stealth to leverage next-generation covalent chemistry, with a mission to accelerate clinical translation and...

Base to Base biotech podcast 70: Taking the lead on GI motility disorders

Jim Cornall -
This week, we have a conversation with Peter G. Milner, founder and director of Renexxion, about GI motility disorders. Base...

Cancer immunotherapy and gene therapy in a single nanoparticle

Jim Cornall -
Cancer cells survive by hiding from the immune system's surveillance. A KAIST research team has developed a new anticancer...